Appendix 4C and Quarterly Activities Report - March 2025
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
30 April 2025
Quarterly Activity Report – Quarter ending 31 March 2025
MELBOURNE – Imagion Biosystems (Company, ASX: IBX), a company dedicated to improving
healthcare outcomes through the early detection of cancer, today releases its Appendix 4C
Quarterly Cashflow and Activities Report for the quarter ending 31 March 2025 (Q1 FY2025).
Summary of Activities
Activities in the first quarter have been consistent with the expected use of funds previously
disclosed as the Company continued to progress the MagSense® HER2 breast cancer imaging
agent program towards its next key milestone of filing an Investigational New Drug (IND)
application with the U.S. Food and Drug Administration (FDA). Obtaining IND approval from the
FDA will allow the Company to undertake the next phase of clinical study investigations which
aims to optimize key testing parameters and to establish the potential diagnostic performance of
this first-of-its-kind molecular MRI platform.
As announced in February, the Company had initiated manufacturing of the MagSense® HER2
imaging agent which is intended to be used in the Phase 2 study. Manufacturing of the imaging
agent is expected to be completed in time to support the filing of the IND application.
Additionally, the Company began communications with many of the leading hospitals and cancer
centers that would be likely study sites and believes there will be strong support for the study in
the U.S.
2025 Outlook
The Company anticipates filing the IND in the third quarter and aims to begin the MagSense® HER2
Breast Cancer Phase 2 study later in the second half of the year pending review and approval by
the U.S. FDA.
Advancing the R&D programs for both prostate cancer and ovarian cancer are expected to
commence in the second half of the year pending the availability of funds.
Summary of cash flows
Please see attached Appendix 4C. Imagion’s cash balance as at 31 March 2025 was AU$1.71
million, a decrease of AU$0.96 million from the prior quarter. The Company reported an operating
cash outflow of AU$0.959 million in the quarter. Operating cash outflows increased by AU$0.297
million from the prior quarter largely due to increased research & development expenditure
associated with the MagSense® HER2program. The Company anticipates similar operating cash
outflow for the next quarter.
The Company paid AU$115,816 to related parties and their associates during the March quarter,
primarily for Directors fees and reimbursable expenses.
ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular
imaging technology. Combining biotechnology and nanotechnology, the Company aims to
detect cancer and other diseases earlier and with higher specificity than is currently possible.
For more information, visit https://imagionbiosystems.com/investor-hub/
Authorisation & Additional information
This announcement was authorised by the Board of Imagion Biosystems Limited.
Media & Investor Relations:
Email: info@imagionbio.com
AU: +61 3 9692 7222
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Imagion Biosystems Limited
ABN
Quarter ended (“current quarter”)
42 616 305 027
31 March 25
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (3
months)
$A’000
-
-
(572)
(572)
(b) product manufacturing and operating
costs
-
-
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs
(53)
(53)
(f)
(349)
(349)
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
17
17
1.5
Interest and other costs of finance paid
(2)
(2)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(959)
(959)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (3
months)
$A’000
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
-
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
-
-
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
2,670
2,670
(959)
(959)
-
-
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (3
months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
-
-
4.5
Effect of movement in exchange rates on
cash held
(2)
(2)
4.6
Cash and cash equivalents at end of
period
1,709
1,709
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
1,709
2,670
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
1,709
2,670
6.
Payments to related parties of the entity and their
associates
Current quarter
$A'000
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
116
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
10,780
-
7.4
Total financing facilities
10,780
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
10,780
The Company has an updated $15 million convertible note facility with Mercer Street
Global Opportunity Fund, LLC, as approved by shareholders at the General Meeting on 22
August 2024, with all terms and conditions of the amended Mercer funding facility set out in
the Notice of Meeting dated 18 July 2024. The Company currently has $10.78 million undrawn
at March quarter end. The facility is secured by a first ranking general security granted by the
Company in favour of Mercer, subject to permitted securities interests.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(959)
8.2
Cash and cash equivalents at quarter end (item 4.6)
1,709
8.3
Unused finance facilities available at quarter end (item 7.5)
10,780
8.4
Total available funding (item 8.2 + item 8.3)
12,489
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
13.02
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
30 April 2025..................................................................................
Authorised by: the Board of Imagion Ltd.................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover